Amphastar Pharmaceuticals (AMPH) versus The Competition Critical Contrast

Amphastar Pharmaceuticals (NASDAQ: AMPH) is one of 110 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Amphastar Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, risk, valuation, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Amphastar Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals 0.12% 2.30% 1.74%
Amphastar Pharmaceuticals Competitors -2,458.15% -60.01% -7.74%

Earnings and Valuation

This table compares Amphastar Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Amphastar Pharmaceuticals $255.16 million $10.53 million N/A
Amphastar Pharmaceuticals Competitors $8.39 billion $1.12 billion 155.65

Amphastar Pharmaceuticals’ competitors have higher revenue and earnings than Amphastar Pharmaceuticals.

Risk and Volatility

Amphastar Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals’ competitors have a beta of 33.74, indicating that their average share price is 3,274% more volatile than the S&P 500.

Institutional and Insider Ownership

43.9% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Amphastar Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals 0 2 4 0 2.67
Amphastar Pharmaceuticals Competitors 854 3762 6799 185 2.54

Amphastar Pharmaceuticals currently has a consensus price target of $20.33, indicating a potential upside of 9.61%. As a group, “Pharmaceuticals” companies have a potential upside of 26.28%. Given Amphastar Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Amphastar Pharmaceuticals has less favorable growth aspects than its competitors.

Summary

Amphastar Pharmaceuticals competitors beat Amphastar Pharmaceuticals on 7 of the 13 factors compared.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply